These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...

New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new study.